At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 82 enrolled
Drug / intervention
Vitamin D3 +1 moredrug
Likely dose
Vitamin D3 4000IUfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Analysis of the Response of Subjects With Atopic Dermatitis to Oral Vitamin D3 by Measurement of Antimicrobial Peptide Expression in Skin and Saliva
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Nov 13, 2008·Updated Apr 12, 2017
In Brief
A Phase 2 clinical trial evaluating Vitamin D3 and Placebo for Atopic Dermatitis and Psoriasis. Completed, enrolled 82 participants across 3 sites.
Detailed Summary
This study will examine whether administration of oral Vitamin D3 given over 21 days will change the antimicrobial peptide expression in the skin or saliva of subjects with Atopic Dermatitis (AD). This study will help researchers determine if the lack of the expression of antimicrobial peptides in individuals with AD plays a role in the susceptibility to eczema vaccinatum (EV).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAtopic Dermatitis, Psoriasis
CountriesUnited States
CollaboratorsConsortium of Food Allergy Research
Timeline
Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2008
Enrollment StartDec 2008
Primary CompletionDec 2009
TodayJul 2026
First PostedNov 13, 2008
Enrollment StartDec 1, 2008
Primary CompletionDec 1, 2009
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 17.6 years ago
Interventions
Vitamin D3drug
Administration of oral vitamin D3 at 4000IU
Placebodrug
Administration of oral Vitamin D3 placebo